Clinical and serologic baseline and follow-up features of syphilis according to hiv status in the post-HAART Era

Medicine

Volumn 88, Issue 6, 2009, Pages 331-340

  Farhi, David ^a   Benhaddou, Nadjet ^a   Grange, Philippe ^b   Zizi, Nada ^a   Deleuze, Jean ^a   Morini, Jean Pierre ^a   Gerhardt, Philippe ^a   Krivine, Anne ^c   Avril, Marie Françoise ^a   Dupin, Nicolas ^a,b  

^a Université Paris 5 René Descartes ^*  (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL SAINT VINCENT DE PAUL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BENZATHINE PENICILLIN; DOXYCYCLINE; PENICILLIN G;

ADULT; AGED; ARTICLE; BISEXUAL MALE; CLINICAL FEATURE; COHORT ANALYSIS; CONDOM; CONTROLLED STUDY; DISEASE COURSE; EUROPE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NEUROSYPHILIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SEROLOGY; SEXUALLY TRANSMITTED DISEASE; SINGLE DRUG DOSE; SYPHILIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREPONEMA PALLIDUM HEMAGGLUTINATION TEST; UNIVERSITY HOSPITAL; VENEREAL DISEASE REACTION TEST;

ADOLESCENT; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SYPHILIS; SYPHILIS SERODIAGNOSIS; YOUNG ADULT;

EID: 72949120903     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/MD.0b013e3181c2af86     Document Type: Article

References (39)

1. Berkelhamer S, Borock E, Elsen C, Englund J, Johnson D. Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children. Clin Infect Dis. 2001;32:1090-1094.
2. Berry CD, Hooton TM, Collier AC, Lukehart SA. Neurologic relapse after benzathine penicillin therapy for secondary syphilis in a patient with HIV infection. N Engl J Med. 1987;316:1587-1589
3. British Association for Sexual Health and HIV. Clinical Effectiveness Group. UK National Guidelines on the Management of Syphilis 2008. URL: http://www.bashh.org/documents/1771. Accessed 02/08/2008.
4. Cameron DW, Simonsen JN, D'Costa LJ, Ronald AR, Maitha GM, Gakinya MN, Cheang M, Ndinya-Achola JO, Piot P, Brunham RC, et al. Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. Lancet. 1989;2:403-407.
5. Chesson HW, Heffelfinger JD, Voigt RF, Collins D. Estimates of primary and secondary syphilis rates in persons with HIV in the United States, 2002. Sex Transm Dis. 2005;32:265-269.
6. Darrow WW, Echenberg DF, Jaffe HW, O'Malley PM, Byers RH, Getchell JP, Curran JW. Risk factors for human immunodeficiency virus (HIV) infections in homosexual men. Am J Public Health. 1987;77:479-483.
7. Farhi D, Dupin N. Infections sexuellement transmissibles: syphilis, urethrites et condylomes. In: Bessis D, ed. Manifestations Dermatologiques des Maladies Infectieuses, Metaboliques et Toxique. Dermatologie et Medecine. vol 2. Paris: Springer; 2008.
8. Fiumara NJ. Treatment of secondary syphilis: an evaluation of 204 patients. Sex Transm Dis. 1977;4:96-99.
9. Fiumara NJ. Treatment of seropositive primary syphilis: an evaluation of 196 patients. Sex Transm Dis. 1977;4:92-95.
10. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect. 1999;75:3-17.
11. Gadkari DA, Quinn TC, Gangakhedkar RR, Mehendale SM, Divekar AD, Risbud AR, Chan-Tack K, Shepherd M, Gaydos C, Bollinger RC. HIV-1 DNA shedding in genital ulcers and its associated risk factors in Pune, India. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:277-281.
12. Ghanem KG, Erbelding EJ, Wiener ZS, Rompalo AM. Serological response to syphilis treatment in HIV-positive and HIV-negative patients attending sexually transmitted diseases clinics. Sex Transm Infect. 2007;83:97-101.
13. Ghanem KG, Moore RD, Rompalo AM, Erbelding EJ, Zenilman JM, Gebo KA. Antiretroviral therapy is associated with reduced serologic failure rates for syphilis among HIV-infected patients. Clin Infect Dis. 2008;47:258-265.
14. Goeman J, Kivuvu M, Nzila N, Behets F, Edidi B, Gnaore E, Van Dyck E, St Louis M, Piot P, Laga M. Similar serological response to conventional therapy for syphilis among HIV-positive and HIV-negative women. Genitourin Med. 1995;71:275-279.
15. Goh BT. Syphilis in adults. Sex Transm Infect. 2005;81:448-452.
16. Goh BT, van Voorst Vader PC. European guideline for the management of syphilis. Int J STD AIDS. 2001;12(Suppl 3):14-26.
17. Golden MR, Marra CM, Holmes KK. Update on syphilis: resurgence of an old problem. JAMA. 2003;290:1510-1514.
18. Gourevitch MN, Selwyn PA, Davenny K, Buono D, Schoenbaum EE, Klein RS, Friedland GH. Effects of HIV infection on the serologic manifestations and response to treatment of syphilis in intravenous drug users. Ann Intern Med. 1993;118:350-355.
19. Hook EW III. Is elimination of endemic syphilis transmission a realistic goal for the USA? Lancet. 1998;351(Suppl 3):19-21.
20. Hutchinson CM, Hook EW III, Shepherd M, Verley J, Rompalo AM. Altered clinical presentation of early syphilis in patients with human immunodeficiency virus infection. Ann Intern Med. 1994; 121:94-100.
21. Janier M, Chastang C, Spindler E, Strazzi S, Rabian C, Marcelli A, Morel P. A prospective study of the influence of HIV status on the seroreversion of serological tests for syphilis. Dermatology. 1999; 198:362-369.
22. Kingston MA, Higgins SP. Comparison of the serological response to treatment of early syphilis in HIV positive versus HIV negative individuals. Sex Transm Infect. 2004;80:152-153.
23. Lafond RE, Lukehart SA. Biological basis for syphilis. Clin Microbiol Rev. 2006;19:29-49.
24. Laurence JC. Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. Am J Med. 2005; 118(Suppl 10A):75S-83S.
25. Lautenschlager S. Cutaneous manifestations of syphilis: recognition and management. Am J Clin Dermatol. 2006;7:291-304.
26. Long CM, Klausner JD, Leon S, Jones FR, Giron M, Cuadros J, Pajuelo J, Caceres C, Coates TJ. Syphilis treatment and HIV infection in a population-based study of persons at high risk for sexually transmitted disease/HIV infection in Lima, Peru. Sex Transm Dis. 2006;33:151-155.
27. Manavi K, McMillan A. The outcome of treatment of early latent syphilis and syphilis with undetermined duration in HIV-infected and HIV-uninfected patients. Int J STD AIDS. 2007;18:814-818.
28. Perdrup A, Jorgensen BB, Pedersen NS. The profile of neurosyphilis in Denmark A clinical and serological study of all patients in Denmark with neurosyphilis disclosed in the years 1971-1979 incl. by Wassermann reaction (CWRM) in the cerebrospinal fluid. Acta Derm Venereol Suppl (Stockh). 1981;96:1-14.
29. Quinn TC, Cannon RO, Glasser D, Groseclose SL, Brathwaite WS, Fauci AS, Hook EW III. The association of syphilis with risk of human immunodeficiency virus infection in patients attending sexually transmitted disease clinics. Arch Intern Med. 1990;150:1297-1302.
30. Radolf JD, Kaplan RP. Unusual manifestations of secondary syphilis and abnormal humoral immune response to Treponema pallidum antigens in a homosexual man with asymptomatic human immunodeficiency virus infection. J Am Acad Dermatol. 1988;18(2 Pt 2):423-428.
31. Riedner G, Rusizoka M, Todd J, Maboko L, Hoelscher M, Mmbando D, Samky E, Lyamuya E, Mabey D, Grosskurth H, Hayes R. Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis. N Engl J Med. 2005;353:1236-1244.
32. Rolfs RT, Joesoef MR, Hendershot EF, Rompalo AM, Augenbraun MH, Chiu M, Bolan G, Johnson SC, French P, Steen E, Radolf JD, Larsen S. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group. N Engl J Med. 1997;337:307-314.
33. Rompalo AM, Joesoef MR, O'Donnell JA, Augenbraun M, Brady W, Radolf JD, Johnson R, Rolfs RT. Clinical manifestations of early syphilis by HIV status and gender: results of the syphilis and HIV study. Sex Transm Dis. 2001;28:158-165.
34. Rottingen JA, Cameron DW, Garnett GP. A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known? Sex Transm Dis. 2001;28:579-597.
35. Telzak EE, Greenberg MS, Harrison J, Stoneburner RL, Schultz S. Syphilis treatment response in HIV-infected individuals. Aids. 1991;5:591-595.
36. Theus SA, Harrich DA, Gaynor R, Radolf JD, Norgard MV. Treponema pallidum, lipoproteins, and synthetic lipoprotein analogues induce human immunodeficiency virus type 1 gene expression in monocytes via NF-kappaB activation. J Infect Dis. 1998;177:941-950.
37. Wasserheit JN. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis. 1992;19:61-77.
38. Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep. 2006;55(RR-11):1-94.
39. Yinnon AM, Coury-Doniger P, Polito R, Reichman RC. Serologic response to treatment of syphilis in patients with HIV infection. Arch Intern Med. 1996;156:321-325.